This video is entirely AI generated and does not replicate any original material. It should not be considered a substitute for authentic sources. For complete context and techniques, viewers are encouraged to refer to the original content.
Based on findings from:
-
General-purpose large language models outperform specialized clinical AI tools on medical benchmarks
Krithik Vishwanath et al.. Nature Medicine, 2026.
DOI: 10.1038/s41591-026-04431-5
-
Real-world performance of a multimodal cell-free DNA multi-cancer early detection test in Asian populations.
Dang Nguyen et al.. Journal of Clinical Oncology, 2026.
DOI: 10.1200/JCO.2026.44.19_suppl.14
-
Development and validation of artificial intelligence-assisted volumetric response criteria in pleural mesothelioma (ARTIMES): a retrospective, multicohort, multicentre study
Kevin Groot Lipman et al.. The Lancet Oncology, 2026.
DOI: 10.1016/S1470-2045(26)00084-7
Weekly News Brief: June 22–26, 2026
To catch up on all of the news from this past week, listen to our weekly news brief for the week of June 22–26, 2026.
This week’s brief covers a controversial study finding that general-purpose AI models outperformed clinical AI tools on medical benchmarks, real-world results from a multi-cancer blood test presented at the ASCO Breakthrough Meeting, and new AI-driven tumor measurement criteria for pleural mesothelioma.
To learn more about clinical vs general-purpose LLMs, read "Study Finding That Foundation Models Outperform Clinical Tools on Medical Benchmarks Sparks Controversy," or see the source report in Nature Medicine.
For more information on SPOT-MAS, read "Machine Learning–Supported MCED Test Demonstrates Real-World Clinical Utility," or see the abstract.
To learn more about ARTIMES, read "AI-Backed Response Criteria Improve Treatment Response Assessments in Pleural Mesothelioma," or see the source report in The Lancet Oncology.
Disclaimer: This newscast was generated with the assistance of AI tools and avatars. All content is reviewed and approved by the editorial staff of ASCO AI in Oncology. Contact us with any questions.
The ideas and opinions expressed in ASCO AI in Oncology do not necessarily reflect those of Conexiant or ASCO. The mention of any company, product, service, or therapy should not be construed as an endorsement of any kind. Conexiant and ASCO assume no responsibility for any injury or damage to persons or property arising out of or related to any use of material contained in this publication or to any errors or omissions.